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Background: Poorer colorectal cancer survival in the United Kingdom than in similar countries may 
be partly due to delays in the care pathway. To address this, cancer waiting time targets were 
established. We investigated if socio-demographic inequalities exist in meeting cancer waiting times 
for colorectal cancer. 
 
Methods: We identified primary colorectal cancers (ICD10 C18-C20; n=35,142) diagnosed 2001-2010 
in the Northern & Yorkshire Cancer Registry area. Using multivariable logistic regression, we 
calculated likelihood of referral and treatment within target by age-group and deprivation quintile.  
 
Results: 48% of patients were referred to hospital within target (<14 days from GP referral  to first 
hospital appointment); 52% started treatment within 31 days of diagnosis; and 44% started 
treatment within 62 days of GP referral. Individuals aged 60-69, 70-79 and 80+ were significantly 
more likely to attend a first hospital appointment within 14 days than those <60 years (adjusted 
OR=1.23 [1.12, 1.34]; 1.19 [1.09, 1.29]; 1.30 [1.18, 1.42] respectively). Older age was significantly 
associated with reduced likelihood of starting treatment within 31 days of diagnosis and 62 days of 
referral. Deprivation was not related to referral within target, but was associated with lower 
likelihood of starting treatment within 31 days of diagnosis or 62 days of referral (most vs least:0.82 
[0.74-0.91]).  
 
Conclusions: Older colorectal cancer patients were less likely to experience referral delays but more 
likely to experience treatment delays. More deprived patients were more likely to experience 
treatment delays. Investigation of patient pathways, treatment decision-making and treatment 
planning would improve understanding of these inequalities.   
 








What is already known about this subject? 
 Pronounced socio-demographic inequalities in receipt of colorectal cancer treatment 
have been demonstrated in many healthcare settings, including the UK.  
 It is unclear whether similar inequalities exist in timeliness of referral or start of 
treatment.  
What this study adds 
 In this large population-based study, older colorectal cancer patients were significantly 
less likely to experience referral delays but more likely to experience treatment delays.  
 The most deprived patients were significantly more likely to experience treatment delays.  
 Timeliness and equity are key features of high quality healthcare. Implementation of 
strategies to reduce these inequalities could reduce psychological distress and improve 





Survival from many cancers is lower for patients in the UK than in similar countries.1 For example, 5-
year age-standardised net survival in the UK for patients diagnosed in 2010-2014 was 58.9% for 
colon cancer and 62.1% for rectal cancer, lower than in Norway, Ireland, Denmark, New Zealand, 
Canada and Australia, where rates of 65-71% were reported.2 This pattern has been evident for 
colorectal (and other) cancers diagnosed since the late 1970s. While UK survival rates have increased 
in recent years, improvements have also been seen elsewhere,3 so the survival gap has not 
narrowed.4 
 
Evidence suggests that this survival gap is due, at least in part, to later stage diagnosis alongside 
inequalities in access to optimal treatment.5,6 Both diagnosis and treatment can be subject to delays. 
Indeed delays can exist across the entire cancer care “pathway” from the first symptom noted by the 
individual through diagnosis to treatment initiation.7,8  These delays can be attributed to both 
patient behaviour and  limitations in the healthcare provider or system.8 
 
The NHS Cancer Plan for England, published in 2000, recognised the possibility of healthcare 
provider or system delays in cancer and established, for the first time, cancer waiting time targets.9 
A target of 14 days between urgent referral (usually from a GP) with symptoms suggesting cancer 
and first assessment by a specialist was established in 2000. For those subsequently diagnosed with 
cancer, treatment should start within 62 days of referral. Since 2005, there has also been a target of 
31 days between the date of the decision-to-treat and start of treatment.  
 
Equity and timeliness are key features of high-quality healthcare.10 Despite this, persistent and 
pronounced socio-demographic inequalities in colorectal cancer treatment receipt have been 
reported. Population-based studies show that older patients and those of lower socio-economic 
status are less likely to receive cancer-directed, or guideline recommended, treatment (see, for 
example, 11-14).   
 
It is less clear whether similar inequalities exist in relation to the cancer waiting time targets or, 
more generally, in timeliness of referral, diagnosis or start of treatment. In the only UK study,  of 
lung cancer,  older patients (aged 80+) were 20% less likely to start treatment within 31 days than 
younger patients (<60).15 North American colorectal cancer studies have reported that older patients 
have longer times between referral and diagnosis or first treatment.16,17 As regards socio-economic 
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status, in Denmark, among a mixed group of cancer patients, those with higher household incomes 
experienced shorter healthcare system delays18 while modestly-sized, non population-based, studies 
in Germany, Jordan and Spain have reported socio-economic patterning in treatment delays for 
colorectal cancer patients.19-21  Evidence from the UK is lacking. 
 
We undertook a large, population-based, study to investigate age and socio-economic inequalities in 




Setting & Data sources 
Data were abstracted on primary colorectal cancers (ICD10 C18-C20) diagnosed 2001-2010 from the 
Northern and Yorkshire Cancer Registry (NYCRIS), which covers a population of 6.8 million resident 
in the North East and most of the Yorkshire and the Humber regions. Cancer notification is 
mandatory; hospitals report cases directly to NYCRIS and this is supplemented by manual data 
collection. The area comprises some densely population urban centres and large rural expanses. 
Cancer care is almost entirely provided in NHS hospitals. At the time of the study, the area had three 
cancer networks, each with several cancer units and a cancer centre providing integrated services. 
The Bowel Cancer Screening Programme, offering home-based faecal occult blood tests, 
commenced in 2006.   
Data were available on age at diagnosis, deprivation category of area of residence at diagnosis (a 
proxy for socioeconomic status (SES) measured using the rank of the income domain of the Index of 
Multiple Deprivation (IMD))22, sex, diagnosis date, tumour site, stage and cancer-directed treatments 
(surgery, radiotherapy, chemotherapy) received by 31/12/2011. Where available, information was 
extracted on dates of referral to hospital by general practitioner (GP), first hospital appointment and 
first cancer-directed treatment. Each record was linked to NHS Hospital Episode Statistics (HES) data 
to provide information on comorbidities. Cancers registered from death certificates only were 
excluded (n=644) as were those with no HES link (n=8,950), leaving 35,142 patients in the dataset. 
 
The study was approved by the NRES Committee East of England REC on 13/12/2011 (reference 





Three binary outcome variables were created representing whether the interval (i) between referral 
and first hospital appointment was ≤14 days (henceforth “referral interval”); (ii) between diagnosis 
and first treatment was ≤31 days (“diagnosis-treatment interval”); and (iii) between referral and first 
treatment was ≤62 days (“referral-treatment interval”). Cases with implausible intervals (e.g. 
treatment date before referral date) were excluded. The referral interval was created for patients 
for whom dates of GP referral and first hospital appointment (surrogate for date of first assessment 
by a specialist) were recorded (n=19,798). The diagnosis-treatment interval was created for patients 
for whom dates of cancer diagnosis (surrogate for the date of the decision-to-treat) and first cancer-
directed treatment were recorded (n=29,445). The referral-treatment interval was created for 
patients for whom dates of GP referral and first cancer-directed treatment were recorded 
(n=17,622). Where dates were not recorded for patients, we assumed they did not apply (e.g. the 
patient was not referred by a GP). 
 
Explanatory variables 
The two main explanatory variables were age (categorised as <60, 60-69, 70-79 and 80+ years) and 
deprivation category (grouped into fifths, based on the national distribution, with the lowest fifth 
(“1”) representing least deprived areas and “5” representing most deprived). IMD2007 was used for 
patients diagnosed 2001-2006 and IMD2010 for those diagnosed 2007 onwards.  
 
To explore whether timeliness had changed over time, year of diagnosis was grouped: 2001-
2005/2006-2010. Cancer stage, assigned using TNM, was categorised as I, II, III, IV, unstaged or 
staged post-treatment. Cancer site was grouped as colon or rectum. Comorbidities influence 
treatment decisions and prognosis in colorectal cancer.23,24 NYCRIS provided a weighted comorbidity 
score based on the Charlson comorbidity index (CCM),25 using the number of relevant in-patient 
admissions (excluding metastatic cancer) recorded in HES in the 3-18 months before the cancer 
diagnosis (Supplementary table S1).  This score was categorised based on the observed distribution: 
none/1-2/3+ comorbidities. Patients were categorised by the first cancer-directed treatment they 
received (cancer-directed surgery/radiotherapy/ chemotherapy). 
 
Statistical analyses 
For each interval (referral; diagnosis-treatment; and referral-treatment), the number and 
percentage of cases referred and treated within target was calculated overall and by age-group, 
deprivation category, and for the other variables.  Logistic regression models were used to estimate 
the odds of referral or treatment within target by age-group and deprivation category with and 
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without adjustment for other variables. The three outcomes were modelled separately. We 
considered variables that were significant in univariate analyses for inclusion in multivariable 
models. We took care to avoid multicollinearity and also eliminated variables that caused poor 
model fit. Cancer site and type of first treatment are strongly correlated; we therefore adjusted the 
referral interval model for site (as this is more pertinent to diagnosis) and the diagnosis-treatment 
and referral-treatment interval models for first treatment. A variable categorising referral interval 
(≤14/>14 days) was considered for inclusion in the referral-treatment model.  Likelihood ratio tests 
were used to determine the overall statistical significance of each variable in the final models. Final 
models had adequate fit. 
 
RESULTS 
Table 1 shows socio-demographic and clinical characteristics of the 35,142 cases. 19,798 (56%) were 
referred by a GP to hospital and were included in the referral interval analysis; 29,445 (84%) 
received cancer-directed treatment and were included in diagnosis-treatment interval analysis; and 
17,622 (50%) were referred by a GP and had cancer-directed treatment and were included in the 
referral-treatment interval analysis.  Sixteen percent of the colorectal cancers were aged ≤60 at 
diagnosis, 24% were 60-69, 34% were 70-79 and 25% were 80+. Slightly less than one fifth were 
resident in the least deprived areas, 57% were male, 61% had colon cancer, 35% had stage I or II 
disease and 13% had comorbidities. In general, compared to this full dataset, the cases included in 
the referral interval, diagnosis-treatment interval and referral-treatment interval analyses were 




Overall, 48% of cases referred to hospital by a GP had their first hospital appointment within 14 
days.  The median referral interval was 16 days (interquartile range (IQR) 9-37 days)(Supplementary 
table S2). 
 
Likelihood of attending a first hospital appointment within 14 days of GP referral is shown in Table 2. 
In  adjusted analysis individuals aged 60-69, 70-79 and 80+ were significantly more likely to attend a 
first hospital appointment within 14 days than those aged <60 years (OR [95% CI]=1.23 [1.12, 1.34]; 
1.19 [1.09, 1.29]; 1.30 [1.18, 1.42] respectively). No significant association between timely first 
hospital appointment and deprivation was found, although the likelihood of timely referral was 
(non-significantly) 5% lower in those resident in the most, compared to the least, deprived fifth. 
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Other factors significantly associated with being more likely to have timely referral were: having 
rectal cancer and having disease that was more advanced than stage I.  
 
Diagnosis-treatment interval 
Fifty-two percent of cases started treatment within 31 days of cancer diagnosis.  The median 
diagnosis-treatment interval was 30 days (IQR 5-49 days) (Supplementary table S2). 
 
Older age was significantly associated with reduced likelihood of starting treatment within 31 days 
of diagnosis (Table 3); after adjustment those aged 60-69, 70-79, and 80+ had reduced odds 
compared to those aged <60 (0.74 [0.68, 0.80]; 0.68 [0.63, 0.73]; and 0.77 [0.71, 0.84] respectively). 
Deprivation was significantly associated with reduced likelihood of starting treatment within target. 
Those resident in deprivation categories 4 and 5 were 9% less likely to receive timely treatment than 
those resident in deprivation category 1.  Other variables significantly associated with being less 
likely to start treatment within 31 days of diagnosis were being male and having chemotherapy 
and/or radiotherapy as the first treatment. More advanced disease was significantly associated with 
starting treatment within 31 days.   
 
Referral-treatment interval  
Overall, 44% of cases referred by a GP started treatment within 62 days of referral.  The median 
referral-treatment interval was 61 days (IQR 49-105 days) (Supplementary table S2). 
 
In multivariable analyses, compared to those aged <60, the two oldest age groups had 10% and 12% 
lower odds, respectively, of starting treatment within 62 days (Table 4). Likelihood of starting 
treatment within target decreased with increasing deprivation and was 0.82 [0.75-0.91] for those in 
the most, compared to the least, deprived category. Other factors significantly associated with not 
starting treatment within 62 days of GP referral were: a referral interval of ≤14 days, receiving 





During 2001-2010, only 48% of colorectal cancer patients referred by a GP attended a first hospital 
appointment within the national target of 14 days, 52% started treatment within 31 days of 
diagnosis and 44% waited ≤62 days between GP referral and start of treatment.  Older age was 
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significantly positively associated with having a first hospital appointment within target, but 
negatively associated with starting treatment within 31 days of diagnosis or 62 days of GP referral.  
Greater deprivation was significantly associated with being less likely to start treatment within 31 
days of diagnosis and 62 days of GP referral; the effect was more pronounced for the referral-
treatment interval and remained after adjustment for having a first hospital appointment within 14 
days of GP referral.    
 
Strengths & Limitations 
To our knowledge, this is the first UK population-based study of inequalities in timeliness of 
colorectal cancer diagnosis and treatment.  Although the data source (NYCRIS) has a high level of 
completeness,14 it covers only the north of England, potentially limiting generalisibility. Nationally, in 
2006-2008, 65% of colorectal cancers were diagnosed through a route originating from a GP referral; 
the remainder were emergency presentations (26%), screen-detected (2%), identified as having 
cancer only at the time of death (1%) or had an unknown route (6%).26 In our analysis, 56% 
(19,798/35,142) of cases had GP referral and first cancer-directed treatment dates, suggesting that 
some cases which originated at the GP may be missing from our analyses, perhaps because referral 
dates were not recorded either in medical records or by the Registry. Since our focus was 
comparisons within the group of patients referred by GPs, this is unlikely to impact internal validity. 
Eighty-four percent (29,445/35,142) of the study population were included in the diagnosis-
treatment interval analysis, broadly consistent with the proportion of colorectal cancers reported as 
having cancer-directed treatment in other European population-based series.12 Although we 
accounted for comorbidity, the Charlson index as applied to HES data captures information only on 
conditions requiring an in-patient stay, meaning we probably underestimated comorbidity. Socio-
economic status was assessed using an area-based measure so may be subject to some 
misclassification.  
 
GPs can refer patients with suspected cancer symptoms as urgent or non-urgent (standard) and the 
14 day target technically applies only to urgent referrals. A weakness of the data is that we were 
unable to distinguish between urgent and non-urgent referrals. In addition, we did not have access 
to data after 2010.  It is important to determine whether socio-demographic variations remain, 
especially given that the national operational standards for timely referral and treatment are 




The 31 day target refers to the time from decision-to-treat. NYCRIS does not record this date, so we 
used date of diagnosis as a proxy. These two dates may differ for some patients, meaning it is likely 
we have slightly overestimated the length of the diagnosis-treatment interval. Whether this 
difference will be differential by socio-demographic factors is unclear. In addition, no information 
was available on any cancer-directed treatments other than surgery, chemotherapy or radiotherapy. 
 
Interpretation of findings 
The “waiting time paradox”, where people who are more obviously unwell are referred more quickly 
but have worse outcomes, is well recognised in cancer.28 Older cancer patients more often have 
multiple comorbidities.29 Thus, one explanation for the relationship between older age and more 
rapid referral is that patients who have multiple health problems (and seem sicker) are more likely 
to be urgently referred. However, we adjusted for comorbidities, albeit imperfectly, so it seems 
unlikely that this is the full explanation. Older patients may be more likely to present with “alarm 
symptoms” (e.g. rectal bleeding). New onset alarm symptoms are more predictive of cancer in older 
people.30 Because of this, and because colorectal cancer incidence increases with age, GPs’ index of 
suspicion of cancer may be higher in older than younger patients hence stimulating urgent referral 
of older patients. “Direct to test” services - where younger, fit, patients go straight from the GP to 
colonoscopy, while older patients (especially the oldest old) wait for an initial specialist 
appointment, then may have a less invasive test (such as CTC or barium enema) before cancer 
diagnosis- are also likely to result in a shorter interval from referral to cancer diagnosis in younger 
patients. 
 
There was a modest (albeit non-significant) association between greater deprivation and lower 
likelihood of being seen at hospital within 14 days of GP referral, consistent with UK lung cancer 
findings.15 In general, lower socio-economic status is associated with suboptimal healthcare use, 
perhaps due to more limited health literacy translating into difficulty navigating healthcare 
systems.31  Research on barriers to medical help-seeking around cancer shows people of  lower 
socio-economic status are less confident talking to the GP about symptoms.32 raising the possibility 
that higher socio-economic status  patients are better able to articulate symptoms and problems  
stimulating  urgent referral.  
 
The diagnosis-treatment interval is the window within which treatment decisions are made and 
patients readied for treatment.  Assessing patient suitability for treatment may take longer in older 
patients particularly if geriatric assessments or referral to other specialities (e.g. cardiology) are 
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needed; this information is not generally recorded by cancer registries.  Limitations in physical 
functioning and/or nutritional status, such as sarcopenia, malnourishment and iron-deficiency 
anaemia, are more common in older colorectal cancer patients.33,34 Patients may need interventions 
to address these before undergoing surgery. This could delay start of treatment and explain the 
observed negative association between increasing age and likelihood of starting treatment within 31 
days.  
 
The observed association between greater deprivation and lower likelihood of starting treatment 
within 31 days of diagnosis, or 62 days of referral, is consistent with associations between delayed 
treatment and lower education and general (vs private) health insurance  in Spain21 and Germany,19 
respectively. Colorectal cancer patients with lower socio-economic status more often have comorbid 
conditions29 which may lengthen treatment planning. We adjusted for comorbidities, but residual 
confounding is possible.  
 
The increasing emphasis on patient-centred care in the NHS has led to more shared and informed 
decision-making. Past work shows that lack of comprehension by patients (as a result of poor health 
literacy) of risks and benefits of elective surgery can lead to decision conflict.35 We might, therefore, 
speculate that, as a result of limited health literacy, colorectal cancer patients from more deprived 
areas may struggle with treatment decision making and this could lead to delays; however, we are 
not aware of any empirical data supporting this.  
 
Implications 
Although evidence is inconsistent on whether more rapid referral influences stage at diagnosis and 
more rapid start of treatment influences survival (at least when relatively short time windows are 
considered),36-37   timeliness and equity are key elements of high quality healthcare.10 Moreover, the 
time waiting for a hospital appointment to investigate suspected cancer or for treatment to start in 
those with a confirmed diagnosis is associated with considerable patient anxiety and distress.38,39 
Therefore, given that the NHS has set cancer waiting time targets, the system should seek to provide 
all patients with a definitive diagnosis and to start treatment in a timely manner.   
 
The question then arises of how to achieve this. Some encouraging findings have been reported for 
patient navigation programmes, which are intended to promote access to timely cancer diagnosis 
and treatment.40 This raises the possibility that allocating some patients (perhaps those who are 
older, more deprived, or have inadequate health literacy) a designated navigator, from within the 
12 
 
hospital care team, could help shorten the time to treatment and reduce or eliminate some of the 
disparities observed here. 
 
However, there may be disadvantages of rapid diagnosis or treatment commencement; Canadian 
studies show that colorectal cancer patients who waited longer for diagnosis or treatment more 
often received higher quality care.41,42 While we were unable to measure clinical aspects of quality of 
care, these findings indicate that relationships between timeliness, utilization and care quality are 
complex.  
 
The findings here – both in terms of the proportions of patients first seen at hospital or treated 
within target, and the socio-demographic patterning - raise many questions. Research is needed to 
quantify: how many, and which, patients need additional time to make treatment decisions; how 
often more time is needed for treatment planning (e.g. for complex patients) or prehabilitation; and 
how often failures to meet targets are due to lack of capacity, lack of equipment or delays reporting  
test results. Recent qualitative research in Northern England among upper GI cancer patients 
diagnosed through the two-week wait pathway found that they often have complex diagnostic 
journeys visiting multiple hospital and primary care sites and may wait considerable time for results 
of tests and investigations.43 Further research is needed to shed light on patient pathways, 
treatment decision-making and treatment planning overall and for different patient subgroups. This 
would help better understand inequalities like those reported here, why the system fails to meet the 
national operating standards27 and what changes are needed if these standards are to be met.  
 
The 2000 NHS Cancer Plan stated that “Where patients wait longer, this should be because of the 
needs of the diagnostic process or their personal choice, not because of built-in delays in the system 
of care”.9  Addressing the socio-demographic inequalities observed here in relation to timely referral 
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Table 1. Demographic and clinical characteristics of colorectal cancers diagnosed 2001-2010, and 













 % % % % 
Age     
<60 years 16.2 16.6 18.4 18.1 
60-69 years 24.4 26.6 26.9 28.6 
70-79 years 34.2 35.3 35.2 35.9 
80+ years 25.2 21.5 19.5 17.5 
     
Deprivation category     
1 (least deprived) 17.6 18.1 18.5 18.8 
2 19.3 19.6 19.8 19.8 
3 18.7 19.2 18.8 19.2 
4 20.8 20.4 20.4 20.2 
5 (most deprived) 23.6 22.7 22.5 22.0 
     
Sex     
Female 42.7 41.6 41.4 40.9 
Male 57.3 58.4 58.6 59.1 
     
Site     
Colon 61.3 53.2 60.5 52.6 
Rectal 38.7 46.8 39.5 47.4 
     
First treatment     
Surgery 65.2 64.9 77.7 73.4 
Chemotherapy 7.0 8.0 8.3 9.1 
Radiotherapy 7.3 9.6 8.7 10.8 
Chemo/radiotherapy 4.4 6.0 5.3 6.7 
No cancer-directed 
 treatment5 
16.1 11.5 - - 
     
Period of diagnosis     
2001-2005 56.9 56.0 57.5 55.7 
2006-2010 43.1 44.0 42.5 44.3 
     
Stage      
I 10.7 12.2 12.5 13.5 
II 24.5 25.3 28.9 28.2 
III 22.4 22.4 26.4 25.2 
IV 22.6 20.9 17.5 16.9 
Unstaged 14.1 11.4 8.0 7.3 
Staged post-treatment 5.7 7.9 6.8 8.9 
     
Comorbidities     
None 86.5 89.6 88.2 90.6 
1-2 11.0 8.8 9.8 8.1 
3+ 2.5 1.6 2.0 1.4 
1 interval between GP referral and first hospital appointment; includes cases for whom date of GP referral and 
date of first hospital appointment were available 
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2 interval between diagnosis and first cancer-directed treatment; includes cases for whom date of diagnosis 
and date of first cancer-directed treatment were available 
3 interval between GP referral and first cancer-directed treatment; includes cases for whom date of GP referral 
and date of first cancer-directed treatment were available 
4 first chemotherapy and radiotherapy received on the same day 




Table 2. Referral interval1 by socio-demographic and clinical characteristics  
   Univariable Multivariable 
 N % OR 95% CI p OR3 95% CI p 
All cases 9461 47.8       
         
Age     <0.001   <0.001 
<60 years 1459 44.4 1.00 -  1.00 -  
60-69 years 2570 48.8 1.19 1.09, 1.30 <0.001 1.23 1.12, 1.34 <0.001 
70-79 years 3323 47.5 1.33 1.04, 1.23 0.003 1.19 1.09, 1.29 <0.001 
80+ years 2109 49.7 1.24 1.13, 1.35 <0.001 1.30 1.18, 1.42 <0.001 
         
Deprivation category     0.292   0.126 
1 (least deprived) 1713 47.8 1.00   1.00   
2 1879 48.5 1.03 0.94, 1.13 0.549 1.02 0.93, 1.12 0.637 
3 1827 48.0 1.01 0.92, 1.11 0.842 0.99 0.91, 1.09 0.895 
4 1931 47.8 1.00 0.91, 1.09 0.983 0.98 0.90, 1.08 0.715 
5 (most deprived) 2111 46.9 0.97 0.88, 1.05 0.438 0.95 0.87, 1.03 0.214 
         
Sex     0.508    
Female 3910 47.5 1.00      
Male 5551 48.0 1.02 0.96, 1.08 0.508    
         
Site     <0.001   <0.001 
Colon  4791 45.5 1.00   1.00   
Rectal 4670 50.4 1.22 1.15, 1.29 <0.001 1.22 1.15, 1.30 <0.001 
         
Period of diagnosis     <0.001    
2001-2005 5422 48.9 1.00      
2006-2010 4039 46.3 0.90 0.85, 0.95 <0.001    
         
Stage      <0.001   <0.001 
I 990 41.1 1.00   1.00   
II 2263 45.3 1.18 1.07, 1.30 0.001 1.23 1.11, 1.36 <0.001 
III 2073 46.7 1.25 1.13, 1.39 <0.001 1.29 1.17, 1.43 <0.001 
IV 2196 53.0 1.61 1.46, 1.78 <0.001 1.67 1.51, 1.85 <0.001 
Unstaged 1131 50.2 1.44 1.28, 1.62 <0.001 1.40 1.24, 1.57 <0.001 
Staged post -treatment 808 51.9 1.55 1.36, 1.76 <0.001 1.46 1.28, 1.66 <0.001 
         
Comorbidities     0.764    
None 8500 47.9 1.00      
1-2 806 46.1 0.93 0.84, 1.03 0.156    
3+ 155 49.8 1.08 0.86, 1.35 0.501    
Figures are numbers and percentages of cases with first hospital appointment ≤14 days from GP referral, 
univariable and multivariable odds ratios (OR), 95% confidence intervals (CI) and p values2 
 
1 interval between GP referral and first hospital appointment; includes 19,798 cases for whom date of GP 
referral and date of first hospital appointment were available 
2 P values in bold are from likelihood ratio tests of the contribution of the variable to the model. Unbolded P 
values are from a test of whether the OR is different from 1 
3 ORs are mutually adjusted; the inclusion of period of diagnosis resulted in poor model fit, so it was not 




Table 3. Diagnosis-treatment interval1 by socio-demographic and clinical characteristics  
   Univariable Multivariable 
 N % OR 95% CI p OR3 95% CI p 
All cases 15222 51.7       
         
Age     <0.001   <0.001 
<60 years 2881 53.3 1.00   1.00   
60-69 years 3905 49.2 0.85 0.79, 0.91 <0.001 0.74 0.68, 0.80 <0.001 
70-79 years 5174 50.0 0.88 0.82, 0.94 <0.001 0.68 0.63, 0.73 <0.001 
80+ years 3262 56.7 1.15 1.07, 1.24 <0.001 0.77 0.71, 0.84 <0.001 
         
Deprivation category     <0.001   0.013 
1 (least deprived) 2888 53.0 1.00   1.00   
2 3063 52.7 0.99 0.92, 1.06 0.714 0.97 0.89, 1.05 0.453 
3 2885 52.0 0.96 0.89, 1.04 0.308 0.96 0.88, 1.04 0.301 
4 3071 51.1 0.93 0.86, 0.99 0.041 0.91 0.84, 0.99 0.027 
5 (most deprived) 3315 50.1 0.89 0.83, 0.95 0.001 0.91 0.84, 0.98 0.019 
         
Sex     <0.001   <0.001 
Female 6738 55.3 1.00   1.00   
Male 8484 49.2 0.78 0.75, 0.82 <0.001 0.88 0.84, 0.93 <0.001 
         
First treatment     <0.001   <0.001 
Surgery  14245 62.2 1.00   1.00   
Chemotherapy 583 23.8 0.19 0.17, 0.21 <0.001 0.11 0.10, 0.13 <0.001 
Radiotherapy 245 9.6 0.06 0.06, 0.07 <0.001 0.05 0.04, 0.06 <0.001 
Chemo/radiotherapy4 149 9.6 0.06 0.05, 0.08 <0.001 0.05 0.04, 0.06 <0.001 
         
Period of diagnosis     <0.001    
2001-2005 9114 53.8 1.00      
2006-2010 6108 48.9 0.82 0.78, 0.86 <0.001    
         
Stage      <0.001   <0.001 
I 1883 51.1 1.00   1.00   
II 4894 57.5 1.29 1.20, 1.40 <0.001 1.31 1.21, 1.42 <0.001 
III 4498 57.9 1.32 1.22, 1.43 <0.001 1.40 1.29, 1.52 <0.001 
IV 2499 48.6 0.91 0.83, 0.99 0.023 2.31 2.09, 2.57 <0.001 
Unstaged 1246 52.9 1.08 0.97, 1.19 0.165 2.69 2.38, 3.05 <0.001 
Staged post -treatment 202 10.2 0.11 0.09, 0.13 <0.001 1.62 1.32, 1.98 <0.001 
         
Comorbidities     0.020    
None 13385 51.5 1.00      
1-2 1508 52.2 1.03 0.95, 1.11 0.472    
3+ 329 56.5 1.22 1.04, 1.44 0.017    
Figures are numbers and percentages of cases who started treatment ≤31 days of date of diagnosis, 
univariable and multivariable odds ratios (OR), 95% confidence intervals (CI) and p values2 
 
1 interval between diagnosis and first cancer-directed treatment; includes 29,445 cases for whom date of 
diagnosis and date of first cancer-directed treatment were available 
2 P values in bold are from likelihood ratio tests of the contribution of the variable to the model. Unbolded P 
values are from a test of whether the OR is different from 1 
3 ORs are mutually adjusted; the inclusion of period of diagnosis and comorbidities resulted in poor model fit, 
so these variables were not included in the multivariable model 
4 Chemotherapy and radiotherapy received on the same day  
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Table 4. Referral-treatment interval1 by socio-demographic and clinical characteristics  
   Univariable Multivariable 
 N % OR 95% CI p OR3 95% CI p 
All cases 7690 43.6       
         
Age     0.454   <0.001 
<60 years 1364 42.7 1.00   1.00   
60-69 years 2305 45.8 1.14 1.04, 1.24 0.005 1.05 0.95, 1.16 0.308 
70-79 years 2681 42.4 0.99 0.91, 1.08 0.835 0.90 0.81, 0.99 0.027 
80+ years 1340 43.6 1.04 0.94, 1.15 0.466 0.88 0.79, 0.99 0.027 
         
Deprivation category     <0.001   <0.001 
1 (least deprived) 1513 45.7 1.00   1.00   
2 1601 46.0 1.01 0.92, 1.11 0.806 1.01 0.91, 1.12 0.849 
3 1511 44.6 0.96 0.87, 1.05 0.379 0.95 0.85, 1.06 0.362 
4 1497 42.1 0.86 0.78, 0.95 0.003 0.85 0.77, 0.95 0.004 
5 (most deprived) 1568 40.4 0.81 0.73, 0.88 <0.001 0.82 0.74, 0.91 <0.001 
         
Sex     0.080    
Female 3200 44.4 1.00      
Male 4490 43.1 0.95 0.89, 1.01 0.080    
         
Referral interval     <0.001   <0.001 
≤14 days 5182 63.3 1.00   1.00   
>14 days 2385 25.7 0.20 0.19, 0.21 <0.001 0.17 0.16, 0.19 <0.001 
         
First treatment     <0.001   <0.001 
Surgery  6032 46.6 1.00   1.00   
Chemotherapy 625 39.2 0.74 0.66, 0.82 <0.001 0.35 0.30, 0.40 <0.001 
Radiotherapy 625 32.9 0.56 0.51, 0.62 <0.001 0.21 0.18, 0.24 <0.001 
Chemo/radiotherapy4 408 34.3 0.60 0.53, 0.68 <0.001 0.18 0.15, 0.22 <0.001 
         
Period of diagnosis     <0.001    
2001-2005 3402 34.7 1.00      
2006-2010 4288 54.9 2.30 2.16, 2.44 <0.001    
         
Stage      0.002   <0.001 
I 953 40.1 1.00   1.00   
II 2168 43.6 1.15 1.04, 1.27 0.006 1.10 0.98, 1.22 0.101 
III 1957 44.2 1.18 1.07, 1.30 0.001 1.15 1.03, 1.29 0.014 
IV 1357 45.5 1.25 1.12, 1.39 <0.001 1.80 1.57, 2.07 <0.001 
Unstaged 516 40.0 0.99 0.87, 1.14 0.933 1.56 1.33, 1.82 <0.001 
Staged post -treatment 739 47.1 1.33 1.17, 1.51 <0.001 4.89 4.07, 5.88 <0.001 
         
Comorbidities     0.585    
None 6971 43.7 1.00      
1-2 604 42.4 0.95 0.85, 1.06 0.345    
3+ 115 48.3 1.21 0.93, 1.56 0.153    
Figures are numbers and percentages of cases who started treatment ≤62 days of GP referral, univariable and 
multivariable odds ratios (OR), 95% confidence intervals (CI) and p values2 
 
1 interval between diagnosis and first cancer-directed treatment; includes 17,622 cases for whom date of 
diagnosis and date of first cancer-directed treatment were available 
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2 P values in bold are from likelihood ratio tests of the contribution of the variable to the model. Unbolded P 
values are from a test of whether the OR is different from 1 
3 ORs are mutually adjusted; the inclusion of period of diagnosis resulted in poor model fit, so it was not 
included in the multivariable model 
4 Chemotherapy and radiotherapy received on the same day 
 
 
 
 
 
